# ![@biomeafusion Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1316822976029835264.png) @biomeafusion biomea fusion

biomea fusion posts on X about covalent, fusion, we are, dr the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1316822976029835264/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1316822976029835264/c:line/m:interactions.svg)

- [--] Week [---] +143%
- [--] Month [-----] -12%
- [--] Months [-----] +6.70%
- [--] Year [------] +100%

### Mentions: [--] [#](/creator/twitter::1316822976029835264/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1316822976029835264/c:line/m:posts_active.svg)


### Followers: [-----] [#](/creator/twitter::1316822976029835264/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1316822976029835264/c:line/m:followers.svg)

- [--] Week [-----] -0.03%
- [--] Month [-----] -1%
- [--] Months [-----] -32%
- [--] Year [-----] -55%

### CreatorRank: undefined [#](/creator/twitter::1316822976029835264/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1316822976029835264/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [travel destinations](/list/travel-destinations)  [finance](/list/finance)  [financial services](/list/financial-services)  [countries](/list/countries)  [exchanges](/list/exchanges)  [social networks](/list/social-networks)  [technology brands](/list/technology-brands) 

**Social topic influence**
[covalent](/topic/covalent), [fusion](/topic/fusion), [we are](/topic/we-are), [dr](/topic/dr), [$bmea](/topic/$bmea) #6, [longterm](/topic/longterm), [in the](/topic/in-the), [thank you](/topic/thank-you), [amsterdam](/topic/amsterdam), [strong](/topic/strong)

**Top accounts mentioned or mentioned by**
[@biomeafusioncom](/creator/undefined) [@realtombutler](/creator/undefined) [@diatribenews](/creator/undefined) [@jpmorgan](/creator/undefined) [@ashhematology](/creator/undefined)

**Top assets mentioned**
[Fusion (FSN)](/topic/fusion) [Biomea Fusion, Inc. (BMEA)](/topic/$bmea) [GLP1 (GLP1)](/topic/glp1)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Positive data from BMF-219 trial for #Type2Diabetes COVALENT-111 Cohort [--] results after [--] weeks of once-daily [---] mg dosing of BMF-219: ✅ 89% achieved a reduction in A1c ✅ 78% had a 0.5% reduction in A1c ✅ 56% achieved a 1% reduction in A1c $BMEA https://bit.ly/42FRACB https://bit.ly/42FRACB"  
[X Link](https://x.com/biomeafusion/status/1640688458371833857)  2023-03-28T12:13Z [----] followers, [---] engagements


"👉 New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the #ADA2023 Scientific Sessions 👉 Biomea to hold an investor and KOL event during Scientific Sessions - #ADA #T2D $BMEA #Type2Diabetes #Diabetes https://bit.ly/3KRFzl9 https://bit.ly/3KRFzl9"  
[X Link](https://x.com/biomeafusion/status/1648699278397788166)  2023-04-19T14:45Z [----] followers, [---] engagements


"What exactly is covalency Check out our video to find out what a covalent molecule is. Visit #ADA2023 #Covalency #MeninProtein 4BMEA #BiomeaFusion #T2D #Type2Diabetes #Diabetes https://biomeafusion.com https://biomeafusion.com"  
[X Link](https://x.com/biomeafusion/status/1671527963035066368)  2023-06-21T14:38Z 11.1K followers, [---] engagements


"🎉 Our poster is up at ADA [----] 👉 Find COVALENT-111 Phase 1/2 Trial of BMF-219 an Oral Covalent Menin Inhibitor in Patients with Type [--] Diabetes Mellitus - Preliminary Results in the "Late Breaking" section poster # 91-LB. #T2D #Diabetes #Biotech"  
[X Link](https://x.com/biomeafusion/status/1672421555748446208)  2023-06-24T01:49Z 11K followers, [----] engagements


"What exactly is covalency Check out our video to find out what a covalent molecule is and don't forget to explore our small covalent molecules hematological malignancies solid tumors and #T2D at #ASH23 #MeninProtein #BMEA #BiomeaFusion https://biomeafusion.com https://biomeafusion.com"  
[X Link](https://x.com/biomeafusion/status/1679232993523560450)  2023-07-12T20:55Z 11K followers, [---] engagements


"Honored to have our CEO and Founder @RealTomButler represent us at the HBM Biopharma Summit in Zurich Switzerland Grateful for the opportunity to inspire innovation 💡 What a great conference #HBMPharmaSummit #Biotech #Innovation Learn more about our work in #diabetes at"  
[X Link](https://x.com/biomeafusion/status/1707863019827695991)  2023-09-29T21:00Z 13.2K followers, [--] engagements


"We're grateful to @diaTribeNews for sharing the news of our Type [--] Diabetes clinical trial. Discover more about our study and access diabetes education on diaTribe's website:👉 📚💡"  
[X Link](https://x.com/biomeafusion/status/1719722895566320074)  2023-11-01T14:27Z 13.3K followers, [---] engagements


"November is National Diabetes Awareness Month. We are sharing important statistics and information to help raise awareness of the impact of #diabetes. More than [--] million Americans are living with diabetes. We are working tirelessly on diabetes innovations to support the diabetes community. #DiabetesAwarenessMonth #DiabetesMonth #DiabetesFacts #Diabetes #T1D #T2D #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1721992464553164852)  2023-11-07T20:46Z 13.3K followers, [--] engagements


"Care for people living with diabetes accounts for [--] in [--] health care dollars in the U.S. On average people living with diabetes pay almost $20000 a year for medical care which on average is [---] times higher than what would be expected without diabetes. A cure would help relieve the cost of diabetes. We continue to work on our discovery and innovations with a curative intent in diabetes. #DiabetesAwarenessMonth #DiabetesAwareness #DiabetesFacts #CostofDiabetes #Diabetes #T1D #T2D #Biomea #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1729473454481842323)  2023-11-28T12:12Z 13.2K followers, [--] engagements


"Our Biomea team is exploring various approaches including beta cell regeneration. For millions of Americans a cure would mean freedom from daily insulin injections and blood sugar monitoring. We continue to work on discovery and innovation with an aim for a diabetes-free future. #DiabetesAwarenessMonth #DiabetesAwareness #DiabetesFacts #Diabetes #T1D #T2D #DiabetesCure #Biomea #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1729884806266421569)  2023-11-29T15:27Z 13.2K followers, [---] engagements


"Priyanka Somanath PhD Associate Director at Biomea Fusion presents her talk on BMF-219 in animal models of diabetes and the durable improvement in beta-cell function and glycemic control #Diabetes #T1D #T2D #WCIRDC23 #Biomea #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1732845853818175608)  2023-12-07T19:33Z 13.2K followers, [--] engagements


"Chief Medical Officer Juan Pablo Frias MD took to the stage to kick-off the WCIRDC pre-opening breakfast symposium hosted by Biomea Fusion #Diabetes #T1D #T2D #WCIRDC #Biomea #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1732865021783281985)  2023-12-07T20:49Z 13.2K followers, [---] engagements


"Chief Executive Officer and Chairman of the Board Tom Butler at #WCIRDC introducing Biomea Fusion and the discovery of the covalent menin inhibitor BMF-219 @RealTomButler #Diabetes #T1D #T2D #WCIRDC #Biomea #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1732871294188744743)  2023-12-07T21:14Z 13.2K followers, [---] engagements


"Priyanka Somanath PhD Associate Director at Biomea Fusion presents her talk on BMF-219 in animal models of diabetes and the durable improvement in beta-cell function and glycemic control. #WCIRDC23 #TeamFusion #Diabetes #T1D #T2D #WCIRDC #Biomea #BiomeaFusion #BiomeaAtWCIRDC #BiomeaBetaCellScience"  
[X Link](https://x.com/biomeafusion/status/1732881201621254459)  2023-12-07T21:54Z 13.2K followers, [---] engagements


"Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after [--] Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type [--] Diabetes in a Poster Presentation at the World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) Read the press release here:"  
[X Link](https://x.com/biomeafusion/status/1733613709027680759)  2023-12-09T22:24Z 13.2K followers, [---] engagements


"Posterpresentation of long-term [--] weeks follow-up data from the first two cohorts of adults with type [--] diabetes enrolled in the ongoing Phase II clinical study (COVALENT-111) and data from preclinical ex-vivo human islet experiments of BMF-219 was held at the World Congress Insulin Resistance Diabetes and Cardiovascular Disease #WCIRDC #Diabetes #DiabetesInnovation #T2D #BiomeaFusion #Biomea #BiomeaBetaCellScience #BiomeaAtWCIRDC"  
[X Link](https://x.com/biomeafusion/status/1733644642917220671)  2023-12-10T00:27Z 11.1K followers, [---] engagements


"📣 Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the [---] mg Dose Cohorts Read more here: #Diabetes #DiabetesInnovation #T2D #BiomeaFusion #Biomea #BiomeaBetaCellScience"  
[X Link](https://x.com/biomeafusion/status/1733922280835588375)  2023-12-10T18:51Z 13.2K followers, [---] engagements


"Our #teamfusion is making a splash at #ash2023 Visit us at our booth #3223 and learn about our #science"  
[X Link](https://x.com/biomeafusion/status/1734011590595289283)  2023-12-11T00:45Z 13.2K followers, [---] engagements


"📢HAPPENING NOW: Biomea Fusion poster presentation tonight until 8:00pm PST at #ASH23. Our Chief Development Officer Steve Morris shares the highlights of our COVALENT-101 study. See you there ➡Poster: 2916"  
[X Link](https://x.com/biomeafusion/status/1734194245966143798)  2023-12-11T12:51Z 11.1K followers, [---] engagements


"📣 Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the [----] ASH Read more #Oncology #OncologyInnovation #AML #BiomeaFusion #Biomea #ASH2023 #ASH"  
[X Link](https://x.com/biomeafusion/status/1734321748085002687)  2023-12-11T21:18Z 13.2K followers, [---] engagements


"📣 Thomas Butler Biomea Fusion's Chief Executive Officer and Chairman of the Board will present recent clinical progress and [----] corporate milestones at the 42ndAnnual J.P. Morgan Healthcare Conference. Read more: @RealTomButler #TeamFusion #JPMorganHealthcare #JPMHC2024 #jpm2024 #DiabetesInnovation"  
[X Link](https://x.com/biomeafusion/status/1744878872762388777)  2024-01-10T00:28Z 13.3K followers, [---] engagements


"We're thrilled to be a part of the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco 🚀 View our presentation at: @jpmorgan #JPMorganHealthcare #JPMHC2024 #JPM2024 #DiabetesInnovation #BiomeaFusion📸: @RealTomButler Juan Pablo Frias Ramses Erdtmann"  
[X Link](https://x.com/biomeafusion/status/1745171712981794953)  2024-01-10T19:52Z 13.2K followers, [---] engagements


"Excited to share key observations from the dose-escalation portion of Covalent-111 our phase 1/2 trial of BMF-219 in patients with type [--] diabetes at #ATTD2024. Join us to learn more about our findings #diabetesresearch #BMF219"  
[X Link](https://x.com/biomeafusion/status/1765291038225084612)  2024-03-06T08:19Z 12.2K followers, [---] engagements


"Excited to present case studies from Covalent-111 our phase 1/2 trial of BMF-219 in patients with type [--] diabetes at #ATTD2024. Join us to learn more about the potential of BMF-219 in personalized diabetes management #diabetesresearch #BMF219"  
[X Link](https://x.com/biomeafusion/status/1765291267062190119)  2024-03-06T08:20Z 12.2K followers, [---] engagements


"Our CMO Juan P. Frias represented us at the National Heart Association of Malaysia Annual Scientific Congress. During the Meet the Expert Event he shared insights on type [--] diabetes and obesity management aligning with our mission for innovative healthcare solutions. Thanks to NHAM for the platform #BiomeaFusion #HealthcareInnovation #NHAM2024 #Type2Diabetes #ObesityManagement"  
[X Link](https://x.com/biomeafusion/status/1787554496073101334)  2024-05-06T18:46Z 11.9K followers, [---] engagements


"Exciting news Biomea Fusion has completed enrollment of the first [--] dose expansion arm in our Phase [--] COVALENT-111 study for BMF-219 in type [--] diabetes Over [---] patients dosed. BMF-219 aims to regenerate insulin-producing beta cells. #DiabetesResearch #BMF219 #HealthcareInnovation Visit for updates https://bit.ly/3V3f0yP http://biomeafusion.com https://bit.ly/3V3f0yP http://biomeafusion.com"  
[X Link](https://x.com/biomeafusion/status/1796198037972226112)  2024-05-30T15:12Z 11K followers, [---] engagements


"Steve Morris Chief Development Officer and Alex Cacovean VP-Clinical Development are excited to announce the presentation of our poster "Covalent-103: A Phase [--] Open-Label Dose Escalation and Expansion Study of BMF-500 an Oral Covalent FLT3 Inhibitor in Adults with Acute Leukemia (AL)" at #ASCO2024 #TeamFusion #leukemia #bmf-500 https://bit.ly/4aYsjq2 https://bit.ly/4aYsjq2"  
[X Link](https://x.com/biomeafusion/status/1799165593255387645)  2024-06-07T19:44Z 11K followers, [----] engagements


"While many health-focused companies use blue or red we see green as a symbol of health and healing. Green represents growth renewal and well-being mirroring our dedication to combating diseases with life-saving research and treatments. To learn more about our mission visit our website. http://www.biomeafusion.com http://www.biomeafusion.com"  
[X Link](https://x.com/biomeafusion/status/1832041940474372321)  2024-09-06T13:03Z [----] followers, [---] engagements


"Excitement is in the Air right before the EASD [----] Conference The energy at the Biomea Fusion booth is electric as we finish getting everything ready. We look forward to connecting with fellow innovators researchers and healthcare professionals at the EASD [----] Conference Our team is here ready to showcase our latest advancements in diabetes care. If youre at the conference dont miss the chance to stop by our booth at #E01 and discover how Biomea Fusion is driving the future of diabetes management. We cant wait to share more and continue these vital conversations"  
[X Link](https://x.com/biomeafusion/status/1833243532770906240)  2024-09-09T20:38Z [----] followers, [---] engagements


"Curious about covalency Watch our video to learn exactly what a covalent molecule is and how it works Explore how our small covalent molecules are driving innovation across hematologic malignancies solid tumors and type [--] and type [--] diabetes. Dive deeper into our science at #Covalency #BiomeaFusion #InnovationInHealthcare #CancerResearch #T2D IF you are at #EASD2024 then come by our booth at E.01 and ask us in person http://biomeafusion.com http://biomeafusion.com"  
[X Link](https://x.com/biomeafusion/status/1833853998081716511)  2024-09-11T13:03Z [----] followers, [---] engagements


"FDA Lifts Clinical Hold on BMF-219 in Type [--] and Type [--] Diabetes Trials REDWOOD CITY Calif. Sept. [--] [----] Biomea Fusion Inc. $BMEA a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Biomeas ongoing Phase I/II clinical trials of the Companys investigational covalent menin inhibitor BMF-219 in type [--] and type [--] diabetes (COVALENT-111 and"  
[X Link](https://x.com/biomeafusion/status/1839377223595466833)  2024-09-26T18:51Z [----] followers, [---] engagements


"Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) Two trial-in-progress oral presentations to feature Phase II study design of oral covalent menin inhibitor BMF-219 in patients with type [--] diabetes (COVALENT-111) and in patients with type [--] diabetes (COVALENT-112) One late breaker oral presentation to highlight two case studies assessing BMF-219 in persons with poorly controlled severe insulin-deficient (SIDD) type [--] diabetes Read the press release: https://bit.ly/3zOIIAP https://bit.ly/3zOIIAP"  
[X Link](https://x.com/biomeafusion/status/1843276452533256338)  2024-10-07T13:05Z [----] followers, [---] engagements


"Biomea Fusion Announces Approval of icovamenib as International Nonproprietary Name for BMF-219 Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells. Today we are announcing that the World Health Organization (WHO) has approved icovamenib as the International Nonproprietary Name (INN) for our lead product candidate BMF-219 and that the United States Adopted Name Council has adopted icovamenib as the United States Adopted Name (USAN) for BMF-219. The suffix -menib stands for menin inhibitor. Read the"  
[X Link](https://x.com/biomeafusion/status/1848350448509485466)  2024-10-21T13:07Z [----] followers, [---] engagements


"Biomea Fusion is thrilled to be featured in aFireside Chatat theEvercore 7th Annual HealthCONx Conference Date:December [--] [----] Time:7:558:15 AM EST Learn more about our groundbreaking advancements and vision for transforming patient care. We look forward to sharing our story with you Click here to watch the #HealthCONx #InnovationInHealth #BiomeaFusion #HealthCONx #EvercoreHealthCONx https://bit.ly/4I9RBep https://bit.ly/4I9RBep"  
[X Link](https://x.com/biomeafusion/status/1861870013914792233)  2024-11-27T20:29Z [----] followers, [---] engagements


"The 66th @ASH_hematology Meeting and Exposition is just around the corner Were curiouswhat are you most excited for at this years conference #ASH24 #MeetUsAtBooth221 #BiomeaFusion #WeAimToCure #HematologyInnovation #HematologyResearch #InnovatingCare #TargetingBetterHealth Cutting edge research Building network Explore new solutions Advance education Cutting edge research Building network Explore new solutions Advance education"  
[X Link](https://x.com/biomeafusion/status/1864390117038657941)  2024-12-04T19:23Z [----] followers, [---] engagements


"Complete response of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor icovamenib (BMF-219) At Biomea Fusion we are thrilled to share the groundbreaking results of icovamenib (BMF-219) a novel covalent menin inhibitor developed by our team. In recent clinical studies icovamenib has shown impressive potential in treating NUP98 fusion-positive acute myeloid leukemia (AML) achieving full complete response in a historically difficult-to-treat leukemia subtype. This exciting development underscores the power of menin inhibition in treating hematologic cancers and"  
[X Link](https://x.com/biomeafusion/status/1865786873303400561)  2024-12-08T15:53Z [----] followers, [---] engagements


"Were excited to sharepreliminary Phase I datafrom our COVALENT-103 study ofBMF-500 our investigational covalent FLT3 inhibitor for relapsed/refractory acute leukemia. Highlights: Promising Efficacy: Reductions in bone marrow blasts in 5/6 FLT3-mutated patients including a first complete response with incomplete hematologic recovery (CRi). Strong Safety: No dose-limiting toxicities observed with excellent tolerability. On-Target Action: Near-complete FLT3 inhibition and bone marrow penetration confirmed. "Leukemia patients with FLT3mutations who have failed existing therapies face devastating"  
[X Link](https://x.com/biomeafusion/status/1866231174533964000)  2024-12-09T21:19Z [----] followers, [---] engagements


"Exciting Update Biomea Fusion will present further icovamenib preclinical data at the 22nd World Congress on Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles Dec 12-14 [----]. Key Highlights: Icovamenib boosts beta cell function and insulin secretion showing synergy with GLP-1 therapies. The combination may allow lower doses of GLP-1 therapies improving tolerability and reducing side effects. Icovamenib's ability to regenerate beta cells offers new hope for diabetes patients especially those with severe insulin deficiency. Join us for our poster presentation"  
[X Link](https://x.com/biomeafusion/status/1867347769184465109)  2024-12-12T23:16Z [----] followers, [---] engagements


"We are excited to announce that Biomea Fusion will host aconference call and webcastto share thetopline resultsfrom our Phase IICOVALENT-111 studyin patients withType [--] Diabetes (T2D). Date: Tuesday December [--] [----] Time: 8:00 AM EST Webcast The COVALENT-111 study evaluatesicovamenib our novel covalent small molecule as a potential new treatment option for patients with Type [--] Diabetes. At Biomea we are dedicated to improving the lives of patients through the discovery and development ofnext-generation covalent therapies. Dont miss this important milestone as we advance our mission to deliver"  
[X Link](https://x.com/biomeafusion/status/1868827590342942869)  2024-12-17T01:16Z [----] followers, [---] engagements


"We are thrilled to announce positive topline results from our ongoing Phase II COVALENT-111 study of icovamenib a potential first-in-class menin inhibitor for Type [--] Diabetes (T2D). Key highlights from the study: * Statistically significant reductions in HbA1c with a placebo-adjusted mean reduction of 1.47% in beta-cell deficient patients after just [--] weeks of [---] mg dosing. * Well-tolerated safety profile with no serious adverse events or discontinuations. * Validated our targeted approach identifying the optimal dose and patient population for icovamenib. These results underscore the"  
[X Link](https://x.com/biomeafusion/status/1869731777239040159)  2024-12-19T13:09Z [----] followers, [---] engagements


"Were unveiling groundbreaking new data on icovamenib at #ATTD2025 in Amsterdam Whats New Fresh clinical insights from the COVALENT-111 study including c-peptide data and long-term beta cell function improvements even [--] weeks post-treatment Exciting combination data with GLP-1 receptor agonists showing potential for enhanced insulin secretion and glycemic control. Icovamenib could be a first-in-class disease-modifying therapy for severe insulin-deficient type [--] diabetes (T2D). Join us at ATTD [----] Oral Presentations March [--] Poster Presentation March [--] Symposium March [--] Stay tuned as we"  
[X Link](https://x.com/biomeafusion/status/1895097727354081357)  2025-02-27T13:04Z [----] followers, [---] engagements


"Icovamenib a first-in-class menin inhibitor that aims to help the body restore the pool of beta cells which are the insulin producing cells in our pancreas. The best part Its a short treatment that can potentially restore the bodys natural ability to produce insulin Learn more about our innovation behind icovamenib #BiomeaFusion #WeAimToCure #InnovationInMedicine #Type2Diabetes https://bit.ly/icovamenib https://bit.ly/icovamenib"  
[X Link](https://x.com/biomeafusion/status/1898403910223532368)  2025-03-08T16:02Z [----] followers, [---] engagements


"Team Fusion has arrived in Amsterdam for the Advanced Technologies & Treatments for Diabetes (ATTD) [----] conference and were excited to connect with you Stop by booth #01B to meet our team and learn more about our work in covalent small molecule therapies for diabetes. Were here to discuss the latest advancements share insights and explore how innovation can transform patient care. What to Expect at Our Booth: 💡 In-depth discussions on our pioneering approach to diabetes treatment 🤝 Opportunities to connect with our experts 📊 The latest updates on our research and clinical progress If"  
[X Link](https://x.com/biomeafusion/status/1902631239158526089)  2025-03-20T08:00Z [----] followers, [---] engagements


"At #EHA2025 we shared new preliminary results for BMF-500 our selective covalent FLT3 inhibitor in relapsed/refractory AML. Early data show sustained deep bone marrow responses (MLFS & CRi) and encouraging survival in patients who had progressed despite prior FLT3 inhibitor therapy. 🔬 Key highlights: Sustained CRi and MLFS in heavily pretreated FLT3-mutant AML patients even those who had failed gilteritinib. 82% of efficacy-evaluable FLT3m patients showed bone marrow blast reduction; nearly half had 50% reduction. Encouraging survival: median overall survival improved to [---] months compared"  
[X Link](https://x.com/biomeafusion/status/1935915015086711144)  2025-06-20T04:18Z [----] followers, [---] engagements


"🚨 Press Release 🚨 At the 61st #EASD2025 we presented new preclinical data showing icovamenib + semaglutide delivered: ✅ Superior glycemic control ✅ Greater weight loss driven by fat reduction ✅ Preserved lean mass We also announced FDA clearance of BMF-650 IND with a Phase I obesity trial on track. 🔗 Presentation: 🔗 Press release: #BiomeaFusion #Biotech #InvestorRelations #MetabolicHealth #BMF650 #WeAimToCure #EASD2025 https://bit.ly/BiomeaPR_EASD25 https://bit.ly/EASD2025presentation https://bit.ly/BiomeaPR_EASD25 https://bit.ly/EASD2025presentation"  
[X Link](https://x.com/biomeafusion/status/1967997899398427118)  2025-09-16T17:03Z [----] followers, [---] engagements


"November marks Diabetes Awareness Month a time to raise awareness for the millions of people living with diabetes worldwide. At Biomea Fusion our mission is to move beyond managing symptoms to address the root causes of disease. Through our covalent small-molecule approach we aim to restore healthy metabolism and help patients live fuller healthier lives. #DiabetesAwarenessMonth #BiomeaFusion #WeAimToCure #MetabolicHealth #Biotech https://twitter.com/i/web/status/1984681909486514270 https://twitter.com/i/web/status/1984681909486514270"  
[X Link](https://x.com/biomeafusion/status/1984681909486514270)  2025-11-01T18:00Z [----] followers, [---] engagements


"We're thrilled to be participating in #ATTD2025 in Amsterdam Join Biomea Fusion as we present groundbreaking insights into our novel therapeutic candidate icovamenib designed for precision diabetes care. Looking forward to sharing these exciting advancements with you. See you in Amsterdam #DiabetesCare #PrecisionMedicine #BiomeaFusion #ATTD2025 https://twitter.com/i/web/status/1901257230638580118 https://twitter.com/i/web/status/1901257230638580118"  
[X Link](https://x.com/biomeafusion/status/1901257230638580118)  2025-03-16T13:00Z [----] followers, [---] engagements


"💚 World Mental Health Day reminder: Managing diabetes is hard work. According to the CDC: 33%50% of people with diabetes experience diabetes distress within any 18-month period. People with diabetes are 20% more likely to experience anxiety. People with diabetes are [--] more likely to experience depression than those without diabetes. These challenges can lead to skipped blood-sugar checks unhealthy coping habits or missed appointmentscreating a cycle that can make diabetes even harder to manage. The good news Prioritizing mental health can create a positive feedback loop improving daily"  
[X Link](https://x.com/biomeafusion/status/1976709318566461773)  2025-10-10T18:00Z [----] followers, [---] engagements


"Biomea Fusion ($BMEA) will discuss menin inhibition recent clinical data for Icovamenib and its potential in Type [--] diabetes during the Jefferies Virtual Fireside Chat. Date: November [--] [----] Time: 11:00 am EST (8:00 am PST) Host: Roger Song Register to listen: #BiomeaFusion #Biotech #Investors #Jefferies #WeAimToCure https://bit.ly/biomea-jefferies-2025 https://bit.ly/biomea-jefferies-2025"  
[X Link](https://x.com/biomeafusion/status/1986886453578641659)  2025-11-07T20:00Z [----] followers, [---] engagements


"We are excited to announce we have been selected for an oral presentation of icovamenib follow up data at the 23rd World Congress on Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) taking place in Los Angeles California on December 3-6 [----]. Read more #BiomeaFusion #BMEA #WCIRDC #Biotech #Investors #WeAimToCure https://bit.ly/press-release-wcirdc-2025 https://bit.ly/press-release-wcirdc-2025"  
[X Link](https://x.com/biomeafusion/status/1995709020720574497)  2025-12-02T04:18Z [----] followers, [---] engagements


"Today is the final day at WCIRDC Visit our poster one of just six oral presentations this year featuring long-term COVALENT-111 data with icovamenib. #WCIRDC2025 #BiomeaFusion #WeAimToCure"  
[X Link](https://x.com/anyuser/status/1997337600747618727)  2025-12-06T16:09Z [----] followers, [---] engagements


"Happy New Year from Team Fusion Were looking ahead to an exciting year with meaningful milestones and continued momentum. Cheers to 2026"  
[X Link](https://x.com/anyuser/status/2007134879385809083)  2026-01-02T17:00Z [----] followers, [---] engagements


"Renowned diabetologist Dr. Ralph DeFronzo explains why pairing menin inhibition with GLP-1 therapy could be a powerful approach treating diabetes. Were excited to be exploring this strategy in our COVALENT-212 combination study with GLP-1 as we continue advancing innovative approaches for metabolic diseases. Watch the full ASTR60 interview with Hartaj Singh: #BiomeaFusion #WeAimToCure #astr60 https://youtu.be/j5VT08LTrt4 https://youtu.be/j5VT08LTrt4"  
[X Link](https://x.com/anyuser/status/2009702342602412175)  2026-01-09T19:02Z [----] followers, [---] engagements


"We are entering [----] with momentum from [----] to advance our metabolic disease pipelines. Anticipated milestones for this year include: COVALENT-211 (Phase IIb): First patient enrollment expected in 1Q [----] with readout of the 26-week primary endpoint evaluating HbA1c reduction in approximately [--] patients expected in 4Q [----]. COVALENT-212 (Phase II): First patient enrollment expected in 1Q [----] with readout of the 26-week primary endpoint evaluating HbA1c reduction in approximately [--] patients expected in 4Q [----]. GLP-131 (Phase I): Completion of single- and multiple-ascending dose cohorts"  
[X Link](https://x.com/anyuser/status/2010743742156693990)  2026-01-12T16:00Z [----] followers, [---] engagements


"Last week we hosted an investor event in the heart of Beverly Hills bringing together investors and industry leaders for thoughtful discussion and meaningful connection. Thank you to everyone who joined uswe appreciate the strong interest insightful questions and continued engagement as we advance our metabolic disease pipeline. #BiomeaFusion #InvestorRelations #Biotech #LifeSciences #MetabolicDisease #Diabetes #Obesity #WeAimToCure https://twitter.com/i/web/status/2010834302561374570 https://twitter.com/i/web/status/2010834302561374570"  
[X Link](https://x.com/anyuser/status/2010834302561374570)  2026-01-12T22:00Z [----] followers, [---] engagements


"Biomea Fusion is proud to share highlights fromMini Balakrishnan PhDspresentation at the22ndAnnual World Congress on Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC 2024). Abstract #0069 Title: Combination of Icovamenib and GLP-1-based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion Key Findings: - Beta Cell Proliferation: Icovamenib demonstrated controlled beta cell proliferation in human islet microtissues ex vivo in a glucose- and dose-dependent manner. - Enhanced Responsiveness: Icovamenib amplified the effects of GLP-1 receptor agonists like semaglutide"  
[X Link](https://x.com/biomeafusion/status/1869821702907277621)  2024-12-19T19:06Z [----] followers, [---] engagements


"We are pleased to announce that members of our leadership team will be in San Francisco this January for the43rd Annual J.P. Morgan Healthcare Conference At Biomea Fusion we are deeply committed to advancing innovative therapies inoncologyanddiabetes. If youd like to meet with us in person wed love to hear from you Visit ourContact Uspage to schedule a one-on-one meeting during the conference Lets shape the future of healthcare together #JPM2024 #Oncology #Diabetes #HealthcareInnovation #Biotech https://bit.ly/3BCFeSW https://bit.ly/3BCFeSW"  
[X Link](https://x.com/biomeafusion/status/1869866085576531993)  2024-12-19T22:03Z [----] followers, [---] engagements


"Biomea Fusion Announces New Preclinical Data Supporting Potential of Icovamenib-Semaglutide Combination You can read the full press release here: We are pleased to share compelling preclinical data demonstrating the potential of icovamenib in combination with semaglutide to significantly enhance outcomes in type [--] diabetes management. Key highlights include enhanced body composition and weight management improved glycemic control and superior HbA1c reduction. These results underscore the potential of icovamenib to enhance the efficacy of GLP-1 therapies offering improved glycemic control and"  
[X Link](https://x.com/biomeafusion/status/1876632894698922388)  2025-01-07T14:12Z [----] followers, [---] engagements


"We would like to announce Biomea Fusions strategic pivot to focus on diabetes and obesity medicines a move inspired by groundbreaking clinical results for our lead candidate icovamenib and our oral small molecule GLP-1 candidate BMF-650. Read full press release here: Key Highlights: Icovamenib: A potential first-in-class menin inhibitor achieving a 1.5% HbA1c reduction in severe insulin-deficient patients with durable effects sustained [--] weeks off therapy. Strong synergy with GLP-1-based therapies and a favorable safety profile. Late-stage trials planned for insulin-deficient diabetes"  
[X Link](https://x.com/biomeafusion/status/1879219721704227235)  2025-01-14T17:31Z [----] followers, [---] engagements


"We are happyto announce that Biomea Fusion will be attending the2025 BIOCEO & Investor Conferencein New York February 10-11 [----]. This event is one of the largest investorconferences on biotechnology. Our team looks forward to sharing insights about ourcovalent small molecule therapies engaging in meaningful discussions and exploring partnershipopportunities that can drive innovation incancerdiabetes and obesity management. Interested in partnering with Biomea Fusion or learning more about our groundbreaking workin oncology diabetes and obesity Lets connect Wed love to meet with you during"  
[X Link](https://x.com/biomeafusion/status/1885002427478262239)  2025-01-30T16:29Z [----] followers, [---] engagements


"Biomea Fusion is Heading to the Barclays 27th Annual Global Healthcare Conference Were excited to announce that Biomea Fusion (Nasdaq: BMEA) will be attending the Barclays 27th Annual Global Healthcare Conference from March 12-14 [----] in Miami FL This premier event brings together top healthcare innovators investors and industry leaders and we look forward to sharing updates on our groundbreaking covalent small molecule therapies in diabetes and obesity. If youd like to connect with our team at the event feel free to reach out Lets talk about the future of targeted therapies and the impact"  
[X Link](https://x.com/biomeafusion/status/1895472792822280193)  2025-02-28T13:55Z [----] followers, [---] engagements


"3 Days to Go Biomea Fusion at Barclays 27th Annual Global Healthcare Conference The countdown is on In just [--] days Biomea Fusion (Nasdaq: BMEA) will be at the Barclays 27th Annual Global Healthcare Conference in Miami FLone of the premier gatherings for healthcare and biotech innovation. Were looking forward to engaging with industry leaders investors and partners as we continue advancing our covalent small molecule therapies for diabetes and obesity. If you're attending and would like to connect reach outwed love to discuss our progress and future opportunities Learn more #BiomeaFusion"  
[X Link](https://x.com/biomeafusion/status/1899113100193792041)  2025-03-10T15:00Z [----] followers, [---] engagements


"What an incredible experience at the Barclays 27th Annual Global Healthcare Conference in Miami Biomea Fusion was honored to be part of such a dynamic gathering of industry leaders investors and innovators shaping the future of healthcare. Our CEO Thomas Butler and COO Ramses Erdtmann had the opportunity to share our progress in covalent small molecule therapies and discuss the potential impact of our work in diabetes and obesity. The conversations were inspiring and the enthusiasm around innovation in biotech was truly energizing. A big thank you to everyone who connected with uswere excited"  
[X Link](https://x.com/biomeafusion/status/1900533843989295450)  2025-03-14T13:05Z [----] followers, [---] engagements


"Join us at #ATTD2025 in Amsterdam for a captivating Breakfast Symposium presented by Biomea Fusion Harnessing Menin Inhibition: Exploring Icovamenib as a Potential First-in-Class Medicine for Precision Diabetes Care Hear from leading experts: Steve Edelman MD Rohit Kulkarni MD PhD and Juan Pablo Frias MD Dive into groundbreaking discussions on innovative approaches in precision diabetes care and explore the exciting potential of Menin inhibition with Icovamenib. Don't miss this opportunity to connect learn and engage #DiabetesCare #PrecisionMedicine #BiomeaFusion #Icovamenib"  
[X Link](https://x.com/biomeafusion/status/1901619624933810222)  2025-03-17T13:00Z [----] followers, [---] engagements


"We are thrilled to share that four of Biomea Fusions esteemed Strategic Advisory Board members have been recognized by the American Diabetes Association in the [----] National Scientific and Health Care Achievement Awards These [--] awards honor leading experts who have made groundbreaking contributions to diabetes care and research. A huge congratulations to: Steven E. Kahn MB ChB - [----] Banting Medal for Scientific Achievement Shingo Kajimura PhD - [----] Outstanding Scientific Achievement Award Barbara B. Kahn MD MS - [----] Albert Renold Award Melanie J. Davies CBE MBChB MD FRCP FRCGP FMedSci -"  
[X Link](https://x.com/biomeafusion/status/1901906468192104824)  2025-03-18T08:00Z [----] followers, [---] engagements


"Happening in [--] hour at Hall B at #ATTD2025 in Amsterdam Join Biomea Fusion for a Breakfast Symposium on: Harnessing Menin Inhibition: Exploring Icovamenib as a Potential First-in-Class Medicine for Precision Diabetes Care Featuring expert speakers: ✅ Steve Edelman MD ✅ Rohit Kulkarni MD PhD ✅ Juan Pablo Frias MD Dont miss this cutting-edge discussion on innovative approaches in precision diabetes care and the exciting potential of Menin inhibition with Icovamenib Fuel up learn and connect See you soon #DiabetesCare #PrecisionMedicine #BiomeaFusion #Icovamenib"  
[X Link](https://x.com/biomeafusion/status/1903288054439186581)  2025-03-22T03:30Z [----] followers, [---] engagements


"For millions of patients with diabetes the disease is an all-consuming reality 📊 24/7 management 💰 High costs 🧠 Brain fog & exhaustion 💉 Uncomfortable treatments 📑 Endless insurance battles At Biomea Fusion were pioneering a breakthrough approach to treating diabetes through targeting menin inhibition to regenerate the beta cell pool and restore endogenous insulin for long-term glycemic control. We want to eliminate the need for chronic treatmentso patients can return to their lives and focus on the other thousand things. To learn more about our diabetes pipeline visit #WeAimToCure"  
[X Link](https://x.com/biomeafusion/status/1905243487718515071)  2025-03-27T13:00Z [----] followers, [---] engagements


"There are no approved therapies exclusively targeting menin yet its role in diabetes treatment holds incredible promise. At Biomea Fusion were changing that. With our cutting-edge molecule icovamenib were taking a groundbreaking approachselectively inhibiting menin to preserve healthy beta cells and restore the bodys natural insulin production. The future of diabetes treatment is evolvingand were leading the way. Learn more about the compelling potential of targeting menin #WeAimToCure #BiomeaFusion #MeninInhibition #BetaCellRegeneration #TheFutureOfMedicine https://bit.ly/biomea-menin"  
[X Link](https://x.com/biomeafusion/status/1905650354013774302)  2025-03-28T15:57Z [----] followers, [---] engagements


"Biomea Fusions Scientific Advisory Board member Dr. Melanie Davies emphasizes the power of targeted treatmentslike icovamenibto address insulin deficiency at its root. Learn more about icovamenib and how targeted therapies are shaping the future of diabetes treatment #PrecisionMedicine #BiomeaFusion #WeAimToCure https://bit.ly/icovamenib https://twitter.com/i/web/status/1909823604251910254 https://bit.ly/icovamenib https://twitter.com/i/web/status/1909823604251910254"  
[X Link](https://x.com/biomeafusion/status/1909823604251910254)  2025-04-09T04:20Z [----] followers, [---] engagements


"In our Type [--] Diabetes Clinical Development Plan Biomea Fusion is prioritizing Severe Insulin-Deficient Diabetes Patients they represent the highest unmet medical need displaying the highest all-cause mortality and worst cardiovascular. We are developing potential therapies aimed at restoring the natural insulin production for these patients with the aim of curing their Type [--] Diabetes. We are advancing precision medicine to meet the unique needs of every patient. Learn more about COVALENT-111 #BiomeaFusion #DiabetesResearch #SIDD #COVALENT111 #PrecisionMedicine #Type2Diabetes"  
[X Link](https://x.com/biomeafusion/status/1914725978133213200)  2025-04-22T17:00Z [----] followers, [---] engagements


"Happy Independence Day from all of us at Biomea Fusion Today we celebrate the spirit of innovation freedom and progress values that drive our mission to transform care for people living with diabetes and obesity. #IndependenceDay #FourthOfJuly #BiomeaFusion #InnovationInHealth #WeAimToCure https://twitter.com/i/web/status/1941180301012574659 https://twitter.com/i/web/status/1941180301012574659"  
[X Link](https://x.com/biomeafusion/status/1941180301012574659)  2025-07-04T17:00Z [----] followers, [---] engagements


"We are pleased to welcome Julianne Averill to the Biomea Fusion Board of Directors effective July [--] [----]. Julianne brings over [--] years of financial operational and strategic leadership across life sciences and digital health. Her deep expertise in capital markets M&A and healthcare innovation will be instrumental as we advance our mission to transform care for patients with diabetes obesity and metabolic diseases. She joins us as a member of the Audit Committee succeeding Bihua Chen whose contributions over the past four years have been invaluable. We extend our sincere gratitude to Bihua"  
[X Link](https://x.com/biomeafusion/status/1948388150713147900)  2025-07-24T14:21Z [----] followers, [---] engagements


"Today is World Lung Cancer Day. A time to honor those affected raise awareness and reaffirm our commitment to changing the trajectory of this devastating disease. At Biomea Fusion were advancing a pipeline of covalent small molecules designed to target the root drivers of cancerincluding lung cancer. Our investigational therapy BMF-500 a next-generation covalent FLT3 inhibitor is currently in development and has shown promise across multiple malignancies including AML and solid tumors. Because when lives are on the line precision matters. 🔗 Learn more about BMF-500 #WorldLungCancerDay"  
[X Link](https://x.com/biomeafusion/status/1951327207025946887)  2025-08-01T17:00Z [----] followers, [---] engagements


"Every year millions of people lose more than their health to diabetes. They lose time. At Biomea Fusion were working to change that by addressing diabetes at its root: restoring and preserving beta cell mass so patients can reclaim more years and more life. Learn about icovamenib's mechanism of action Source #BiomeaFusion #Type2Diabetes #MeninInhibition #WeAimToCureS https://bit.ly/the-lancet-t2d-life-expectancy https://bit.ly/pipeline-and-innovation https://twitter.com/i/web/status/1978581709269418346 https://bit.ly/the-lancet-t2d-life-expectancy https://bit.ly/pipeline-and-innovation"  
[X Link](https://x.com/biomeafusion/status/1978581709269418346)  2025-10-15T22:00Z [----] followers, [---] engagements


"Biomea Fusion ($BMEA) will discuss recent advancements in the development of icovamenib and BMF-650 two investigational programs being studied for metabolic diseases including diabetes and obesity. Date: October [--] [----] Time: 8:00 am 9:00 am PST Host: Yigal Nochomovitz Register to listen: #BiomeaFusion #Biotech #Investors #CitiSMID #WeAimToCure http://bit.ly/biomea-citi-SMID-2025 http://bit.ly/biomea-citi-SMID-2025"  
[X Link](https://x.com/biomeafusion/status/1980725847507050554)  2025-10-21T20:00Z [----] followers, [---] engagements


"Press Release: We are pleased to announce this major milestone in our mission to treat obesity. Read more: https://bit.ly/press-release-first-patient-dosed https://bit.ly/press-release-first-patient-dosed"  
[X Link](https://x.com/biomeafusion/status/1983292958565699647)  2025-10-28T22:01Z [----] followers, [---] engagements


"Biomea Fusion ($BMEA) continues to advance our mission to develop transformative oral therapies for diabetes and obesity. Key Highlights: Icovamenib: 52-Week Phase II data showed durable HbA1c reductions and strong safety profile in T2D patients. BMF-650: First patient dosed in Phase I trial of our next-generation oral GLP-1 RA for obesity. Preclinical synergy: Icovamenib + semaglutide combo demonstrated enhanced glycemic control and weight reduction in T2D animal model. Operational efficiency: Streamlined team to [--] employees and reduced operating expenses by 50%. Strengthened balance sheet:"  
[X Link](https://x.com/biomeafusion/status/1985829591316119789)  2025-11-04T22:00Z [----] followers, [---] engagements


"Biomea Fusion presented new preclinical data at ObesityWeek [----] showcasing progress in diabetes and obesity programs. BMF-650: robust weight loss & tolerability in obese monkeys Icovamenib + low-dose semaglutide: enhanced glycemic control & lean mass preservation Read more #BiomeaFusion #Biotech #Investors #WeAimToCure #ObesityWeek #OW2025 https://bit.ly/press-release-obesity-week-2025 https://twitter.com/i/web/status/1986146575396077777 https://bit.ly/press-release-obesity-week-2025 https://twitter.com/i/web/status/1986146575396077777"  
[X Link](https://x.com/biomeafusion/status/1986146575396077777)  2025-11-05T19:00Z [----] followers, [---] engagements


"Biomea Fusion ($BMEA) will participate in two major investor events next week: Piper Sandler 37th Annual Healthcare Conference Fireside chat at 8:00 AM ET December [--] New York NY Evercore 8th Annual Healthcare Conference Fireside chat at 7:30 AM ET December [--] Coral Gables FL 🎧 Webcasts and replays will be available on our website. Read more #BiomeaFusion #BMEA #PiperSandler #Evercore #EvercoreHealthcare #Biotech #Investors #WeAimToCure https://bit.ly/press-release-upcoming-investor-conferences https://bit.ly/press-release-upcoming-investor-conferences"  
[X Link](https://x.com/biomeafusion/status/1993534687273206222)  2025-11-26T04:18Z [----] followers, [---] engagements


"Biomea Fusion is honored to present new Week [--] long-term follow-up data for icovamenib at WCIRDC [----] in Los Angeles. Selected as one of only six oral presentations our data highlight icovamenibs potential to restore -cell function and address insulin-deficient type [--] diabetes. Oral Presentation Abstract #0062 COVALENT-111: Durable Glycemic and C-Peptide Improvements with Icovamenib December [--] [----] 6:157:45 PM PST Poster and presentation will be available on our website. #WCIRDC2025 #Diabetes #T2D #Icovamenib #MeninInhibitor #BiomeaFusion #MetabolicHealth #Biotech"  
[X Link](https://x.com/anyuser/status/1997158568076710208)  2025-12-06T04:18Z [----] followers, [---] engagements


"Biomea Fusion will be presenting at the J.P. Morgan Healthcare Conference in San Franciscojust down the road from our San Carlos HQ. 📅 Wednesday January [--] [----] 5:155:55 PM PST 📍 The Westin St. Francis Hotel San Francisco For 1:1 meetings please reach out to mweiss@biomeafusion.com. #JPM2026 #HealthcareConference #Biotech #Diabetes #Obesity https://twitter.com/i/web/status/2001691478402183624 https://twitter.com/i/web/status/2001691478402183624"  
[X Link](https://x.com/anyuser/status/2001691478402183624)  2025-12-18T16:30Z [----] followers, [---] engagements


"Join us tomorrow as our CEO Mick Hitchcock Ph.D. presents at the 44th Annual J.P. Morgan Healthcare Conference sharing updates on Biomea Fusions strategy and progress across its metabolic disease pipeline. 📅 Wednesday January [--] [----] 5:155:55 PM PST 📍 The Westin St. Francis Hotel San Francisco For 1:1 meeting requests please contact mweiss@biomeafusion.com. Register for the live webcast #JPM2026 #JPMHealthcare #InvestorRelations #Biotech #LifeSciences #Diabetes #Obesity #HealthcareInnovation http://lnkd.in/gMY7_RnE http://lnkd.in/gMY7_RnE"  
[X Link](https://x.com/anyuser/status/2011098489678147594)  2026-01-13T15:30Z [----] followers, [---] engagements


"Wrapping up an impactful few days at the 44th annual JPMorgan Healthcare Conference. It was a pleasure connecting with investors partners and peers to share updates on Biomea Fusions progress and vision for advancing novel therapies in metabolic disease. Thank you to everyone who attended our presentation met with our team and engaged in thoughtful conversations throughout the week. Were excited to build on this momentum as we dive into [----]. https://twitter.com/i/web/status/2012464344483717196 https://twitter.com/i/web/status/2012464344483717196"  
[X Link](https://x.com/anyuser/status/2012464344483717196)  2026-01-17T09:57Z [----] followers, [---] engagements


"Diabetes is a complex disease that affects how the body regulates blood sugar. Understanding the science behind diabetes is essential to recognizing why researchers continue to explore new approaches. In this video Dr. Biomea explains the role of insulin and the pancreatic beta cells that produce it - helping viewers understand why diabetes often worsens over time. This reinforces Biomea Fusions focus on advancing science-driven solutions that address the root cause of the disease not just the symptoms. https://twitter.com/i/web/status/2014376413378617603"  
[X Link](https://x.com/anyuser/status/2014376413378617603)  2026-01-22T16:35Z [----] followers, [---] engagements


"An afternoon with #TeamFusion celebrating collaboration progress and a strong [----]. Onward to [----]. #BiomeaFusion #WeAimToCure #2026"  
[X Link](https://x.com/anyuser/status/2016300276043465077)  2026-01-28T00:00Z [----] followers, [---] engagements


"Diabetes develops as beta cells gradually lose their ability to produce enough insulin over time. In this segment Dr. Biomea describes how beta cells can become overworked over time leading to reduced insulin production and progressive loss of glucose control. This highlights Biomea Fusions focus on understanding the underlying drivers of disease progression and developing treatments that address the root cause of the disease not just the symptoms. https://twitter.com/i/web/status/2017452790734299517 https://twitter.com/i/web/status/2017452790734299517"  
[X Link](https://x.com/anyuser/status/2017452790734299517)  2026-01-31T04:20Z [----] followers, [---] engagements


"Diabetes develops as beta cells gradually lose their ability to produce enough insulin over time. In this segment Dr. Biomea describes how beta cells can become overworked over time leading to reduced insulin production and progressive loss of glucose control. This highlights Biomea Fusions focus on understanding the underlying drivers of disease progression and developing treatments that address the root cause of the disease not just the symptoms. https://twitter.com/i/web/status/2017452790734299517 https://twitter.com/i/web/status/2017452790734299517"  
[X Link](https://x.com/anyuser/status/2017452790734299517)  2026-01-31T04:20Z [----] followers, [---] engagements


"An afternoon with #TeamFusion celebrating collaboration progress and a strong [----]. Onward to [----]. #BiomeaFusion #WeAimToCure #2026"  
[X Link](https://x.com/anyuser/status/2016300276043465077)  2026-01-28T00:00Z [----] followers, [---] engagements


"Diabetes is a complex disease that affects how the body regulates blood sugar. Understanding the science behind diabetes is essential to recognizing why researchers continue to explore new approaches. In this video Dr. Biomea explains the role of insulin and the pancreatic beta cells that produce it - helping viewers understand why diabetes often worsens over time. This reinforces Biomea Fusions focus on advancing science-driven solutions that address the root cause of the disease not just the symptoms. https://twitter.com/i/web/status/2014376413378617603"  
[X Link](https://x.com/anyuser/status/2014376413378617603)  2026-01-22T16:35Z [----] followers, [---] engagements


"Wrapping up an impactful few days at the 44th annual JPMorgan Healthcare Conference. It was a pleasure connecting with investors partners and peers to share updates on Biomea Fusions progress and vision for advancing novel therapies in metabolic disease. Thank you to everyone who attended our presentation met with our team and engaged in thoughtful conversations throughout the week. Were excited to build on this momentum as we dive into [----]. https://twitter.com/i/web/status/2012464344483717196 https://twitter.com/i/web/status/2012464344483717196"  
[X Link](https://x.com/anyuser/status/2012464344483717196)  2026-01-17T09:57Z [----] followers, [---] engagements


"Join us tomorrow as our CEO Mick Hitchcock Ph.D. presents at the 44th Annual J.P. Morgan Healthcare Conference sharing updates on Biomea Fusions strategy and progress across its metabolic disease pipeline. 📅 Wednesday January [--] [----] 5:155:55 PM PST 📍 The Westin St. Francis Hotel San Francisco For 1:1 meeting requests please contact mweiss@biomeafusion.com. Register for the live webcast #JPM2026 #JPMHealthcare #InvestorRelations #Biotech #LifeSciences #Diabetes #Obesity #HealthcareInnovation http://lnkd.in/gMY7_RnE http://lnkd.in/gMY7_RnE"  
[X Link](https://x.com/anyuser/status/2011098489678147594)  2026-01-13T15:30Z [----] followers, [---] engagements


"As part of our commitment to transparency and engagement we are hosting a Ask Me Anything campaign. Members of our team will be addressing questions from the community. If there is anything in the data or discussion you would like us to expand on please share your question below. https://stocktwits.com/biomearesponder/message/638905858 https://stocktwits.com/biomearesponder/message/638905858"  
[X Link](https://x.com/anyuser/status/2011028498039681415)  2026-01-13T10:52Z [----] followers, [---] engagements


"Last week we hosted an investor event in the heart of Beverly Hills bringing together investors and industry leaders for thoughtful discussion and meaningful connection. Thank you to everyone who joined uswe appreciate the strong interest insightful questions and continued engagement as we advance our metabolic disease pipeline. #BiomeaFusion #InvestorRelations #Biotech #LifeSciences #MetabolicDisease #Diabetes #Obesity #WeAimToCure https://twitter.com/i/web/status/2010834302561374570 https://twitter.com/i/web/status/2010834302561374570"  
[X Link](https://x.com/anyuser/status/2010834302561374570)  2026-01-12T22:00Z [----] followers, [---] engagements


"We are entering [----] with momentum from [----] to advance our metabolic disease pipelines. Anticipated milestones for this year include: COVALENT-211 (Phase IIb): First patient enrollment expected in 1Q [----] with readout of the 26-week primary endpoint evaluating HbA1c reduction in approximately [--] patients expected in 4Q [----]. COVALENT-212 (Phase II): First patient enrollment expected in 1Q [----] with readout of the 26-week primary endpoint evaluating HbA1c reduction in approximately [--] patients expected in 4Q [----]. GLP-131 (Phase I): Completion of single- and multiple-ascending dose cohorts"  
[X Link](https://x.com/anyuser/status/2010743742156693990)  2026-01-12T16:00Z [----] followers, [---] engagements


"Renowned diabetologist Dr. Ralph DeFronzo explains why pairing menin inhibition with GLP-1 therapy could be a powerful approach treating diabetes. Were excited to be exploring this strategy in our COVALENT-212 combination study with GLP-1 as we continue advancing innovative approaches for metabolic diseases. Watch the full ASTR60 interview with Hartaj Singh: #BiomeaFusion #WeAimToCure #astr60 https://youtu.be/j5VT08LTrt4 https://youtu.be/j5VT08LTrt4"  
[X Link](https://x.com/anyuser/status/2009702342602412175)  2026-01-09T19:02Z [----] followers, [---] engagements


"The annual J.P. Morgan Healthcare Conference is just around the corner and were looking forward to sharing updates on our continued progress toward advancing novel therapies for metabolic diseases. 📅 Wednesday January [--] [----] 5:155:55 PM PST 📍 The Westin St. Francis Hotel San Francisco For 1:1 meeting requests please contact mweiss@biomeafusion.com Register for the live webcast #JPM2026 #HealthcareConference #Biotech #Diabetes #Obesity https://bit.ly/biomea-fusion-jp-morgan-2026 https://bit.ly/biomea-fusion-jp-morgan-2026"  
[X Link](https://x.com/anyuser/status/2008629726764498954)  2026-01-06T20:00Z [----] followers, [---] engagements


"Happy New Year from Team Fusion Were looking ahead to an exciting year with meaningful milestones and continued momentum. Cheers to 2026"  
[X Link](https://x.com/anyuser/status/2007134879385809083)  2026-01-02T17:00Z [----] followers, [---] engagements


"Happy Holidays from Team Fusion Wishing you a joyful bright and healthy holiday season. #HappyHolidays"  
[X Link](https://x.com/anyuser/status/2003511026256417079)  2025-12-23T17:00Z [----] followers, [---] engagements


"Managing diabetes with insulin isnt just about medicationits a full-time mental and physical load. Dr. Ralph DeFronzo a world-renowned endocrinologist and diabetes researcher explains why insulin therapy can be so challenging for patients day in and day out. At Biomea patients are at the center of everything we doworking to advance therapies that are not only effective but also convenient and patient-friendly. Watch the full astr60 interview with Hartaj S.: https://youtu.be/j5VT08LTrt4 https://youtu.be/j5VT08LTrt4"  
[X Link](https://x.com/anyuser/status/2003224603162825049)  2025-12-22T22:02Z [----] followers, [---] engagements


"Biomea Fusion will be presenting at the J.P. Morgan Healthcare Conference in San Franciscojust down the road from our San Carlos HQ. 📅 Wednesday January [--] [----] 5:155:55 PM PST 📍 The Westin St. Francis Hotel San Francisco For 1:1 meetings please reach out to mweiss@biomeafusion.com. #JPM2026 #HealthcareConference #Biotech #Diabetes #Obesity https://twitter.com/i/web/status/2001691478402183624 https://twitter.com/i/web/status/2001691478402183624"  
[X Link](https://x.com/anyuser/status/2001691478402183624)  2025-12-18T16:30Z [----] followers, [---] engagements


"A festive afternoon celebrating the team and the year behind us. Cheers to the people driving our mission forward and looking ahead to what's next #TeamFusion #BiomeaFusion #WeAimToCure"  
[X Link](https://x.com/anyuser/status/2001144842814935470)  2025-12-17T04:18Z [----] followers, [---] engagements


"At Biomea were exploring how to harness the body's built-in blueprint for regenerating beta cellswhere menin naturally switches this process on and offas a potential way to restore insulin production in people with diabetes. Watch the full YouTube video as Dr. Ralph DeFronzo a world-renowned leader in diabetes research breaks down the relationship between menin and beta cells key diabetes patient phenotypes our COVALENT-111 study results combination therapy opportunities and more. Watch the full video: https://youtu.be/j5VT08LTrt4 https://youtu.be/j5VT08LTrt4"  
[X Link](https://x.com/anyuser/status/1999193084530180586)  2025-12-11T19:02Z [----] followers, [---] engagements


"Thank you to Dr. Ralph DeFronzoone of the fields most respected and forward-thinking principal investigators in diabetes carefor joining us at WCIRDC [----] with a scientific presentation on the future of menin inhibitors and participating in the ASTR [--] Series interview discussing Biomeas menin inhibitor program webinar on icovamenib Biomeas first-in-class menin inhibitor program. Read full press release: Watch WCIRDC scientific presentation: Watch the ASTR interview: #BiomeaFusion #WCIRDC2025 #menin #icovamenib #WeAimToCure https://youtu.be/j5VT08LTrt4 https://cme.onl/wcirdc/23rd/event.php"  
[X Link](https://x.com/anyuser/status/1998545727941701769)  2025-12-10T00:10Z [----] followers, [---] engagements


"Today is the final day at WCIRDC Visit our poster one of just six oral presentations this year featuring long-term COVALENT-111 data with icovamenib. #WCIRDC2025 #BiomeaFusion #WeAimToCure"  
[X Link](https://x.com/anyuser/status/1997337600747618727)  2025-12-06T16:09Z [----] followers, [---] engagements


"Biomea Fusion is honored to present new Week [--] long-term follow-up data for icovamenib at WCIRDC [----] in Los Angeles. Selected as one of only six oral presentations our data highlight icovamenibs potential to restore -cell function and address insulin-deficient type [--] diabetes. Oral Presentation Abstract #0062 COVALENT-111: Durable Glycemic and C-Peptide Improvements with Icovamenib December [--] [----] 6:157:45 PM PST Poster and presentation will be available on our website. #WCIRDC2025 #Diabetes #T2D #Icovamenib #MeninInhibitor #BiomeaFusion #MetabolicHealth #Biotech"  
[X Link](https://x.com/anyuser/status/1997158568076710208)  2025-12-06T04:18Z [----] followers, [---] engagements


"Thank you Evercore for having us Watch the replay of this morning's Fireside Chat #BiomeaFusion #HealthcareConference #Evercore #DiabetesResearch #InvestorRelations #BMEA #WeAimToCure https://lnkd.in/gh_9hrRx https://lnkd.in/gh_9hrRx"  
[X Link](https://x.com/anyuser/status/1997079089576923506)  2025-12-05T23:02Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing